Cancer Drug Trials Must Be Ready To Pivot As Standards Of Care Shift

 
• By Sue Sutter
  
Changing direction
Cancer drug studies should be designed to pivot if a new standard of care emerges mid-trial. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from United States